Ampholipad Real-World Data in Taiwan

NCT03641131 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 102

Last updated 2021-01-07

No results posted yet for this study

Summary

A retrospective, post-marketing, multi-center chart review study includes patients who had been prescribed Ampholipad.

Conditions

Sponsors & Collaborators

  • Taiwan Liposome Company

    lead INDUSTRY

Principal Investigators

  • Carl Brown, PhD · Taiwan Liposome Company

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-09
Primary Completion
2019-01-02
Completion
2019-01-08

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03641131 on ClinicalTrials.gov